Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer. Despite initial responsiveness, many patients experience rapid relapse driven by cancer stem-like cells that survive chemotherapy and seed metastasis. Addressing this unmet need, researchers have discovered that pitavastatin, a widely prescribed cholesterol-lowering drug, can directly inhibit the anti-apoptotic protein Mcl-1, a key driver of survival, stemness, and paclitaxel resistance in TNBC cells, thereby preventing distant metastasis. The team found that pitavastatin binds specifically to the BH3-binding groove of Mcl-1, disrupting its stability and inducing mitochondrial dysfunction. This inhibition triggered a cascade of mitochondrial damage, leading to ROS...